Dr Byrd discusses optimizing Ibrutinib & Idela... - CLL Support
Dr Byrd discusses optimizing Ibrutinib & Idelalisib.
You need to be a member of this community to see this post.
Read more about...
5 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Dr. Mato on what really happens when we must stop our ibrutinib or idelalisib
Friends,
I hope my US-based readers had a happy healthy holiday weekend. This past weekend, in...
Dr Sharman's thoughts on the race for FDA Approval for Obinituzumab, Ibrutinib and Idelalisib
Following Gilead's announcement regarding Idelalisib:...
Dr. Byrd on COVID-19
Hi,
Dr. John Byrd is not only a valued member of our medical advisory board and a world leader in...
Dr Peter Hillmen of Leeds, UK discusses the place for Idelalisib in CLL treatment (Patient Power Video)
In this short video taken at iwCLL Collogne Germany, Andrew Schorr interviews Dr Hillmen:
"As a...
Your opportunity to support affordable access to Ibrutinib and Idelalisib for Aussies - Submissions close next Wed 7th October
Australia's November Pharmaceutical Benefits Advisory Committe (PBAC) meeting will consider listing...
Related Posts
CLL patients with idelalisib (Zydelig) experience
Possible side effects from Ibrutinib & Idelalisib- Dr. Wiestner on Combos and fixed duration ibrutinib (he doesn't like the idea) and a webinar with Dr. Byrd and me
- ASH 2015: Dr. John M Pagel on the Problems with Idelalisib as Frontline Therapy in CLL
- CLL Society's October 10th Virtual Global Patient Educational Forum, featuring Dr. John Byrd speaking on Clinical Trials!
